Research To Practice | Oncology Videos

Oncology Today with Dr Neil Love: Special Edition — Current Management of Hepatobiliary Cancers — Dr Lipika Goyal Visit our website for more publications

Oncology Today with Dr Neil Love: Special Edition — Current Management of Hepatobiliary Cancers — Dr Zev Wainberg Visit our website for more publications

Featuring perspectives from Dr Sara Tolaney, including the following topics: • Introduction (00:00) • Case: A premenopausal woman in her early 30s with T1c N0 ER/PR-positive, HER2-negative, gBRCA2-mutant invasive ductal carcinoma (IDC) with an Oncotype DX® Recurrence Score® (RS) of 30 receives adjuvant chemotherapy followed by leuprolide/letrozole but wishes to discontinue treatment to attempt pregnancy — Alan B Astrow, MD (10:19) • Case: A woman in her late 30s with T2 N0 ER/PR-positive, HER2-negative IDC and RS of 35 has severe menopause after adjuvant TC, TAH/BSO and letrozole — Ranju Gupta, MD (22:18) • Case: A postmenopausal woman in her early 50s with bilateral ER-positive, HER2-negative breast cancer; RS on the left is low and on the right is 30 but the tumor is 4 millimeters — Zanetta S Lamar, MD (34:19) • Case: A premenopausal woman in her early 40s with a gBRCA2 mutation and Stage IIB ER/PR-positive, HER2-low (IHC 1+) IDC treated with adjuvant tamoxifen develops extensive metastases and receives ovarian function suppression, letrozole and palbociclib — Jeremy Lorber, MD (38:57) • Case: A woman in her early 70s with multiregimen-recurrent ER/PR-positive, HER2-low (IHC 1+) metastatic breast cancer receives T-DXd — Henna Malik, MD (54:25) • Case: A woman in her mid 40s with node-positive localized triple-negative breast cancer has residual disease after neoadjuvant pembrolizumab/chemotherapy and surgery — Laila Agrawal, MD (57:05) CME information and select publications

Featuring perspectives from Dr Matthew Galsky, Jonathan Rosenberg, and Dr Arlene Siefker-Radtke, moderated by Dr Elisabeth Heath, including the following topics: • Integrating Novel Treatment Strategies into the Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Galsky o Introduction (00:00) o Case: A man in his late 70s with superficial transitional cell carcinoma of the bladder after bacillus Calmette-Guérin with positive ureteral washing — Sunil Gandhi, MD (2:38) o Cases: A man in his early 70s with high-grade papillary muscle-invasive bladder cancer with residual disease after neoadjuvant gemcitabine/cisplatin and cystectomy and a man in his early 80s with pT3N0 high-grade urothelial carcinoma after nephroureterectomy (GFR 40) — Ranju Gupta, MD and Swati Vishwanathan, MD (7:04) o Faculty presentation: Dr Galsky (13:16) • Current and Future Front-Line Treatment for Metastatic UBC (mUBC) — Dr Rosenberg o Cases: A man in his mid 70s with metastatic urothelial carcinoma now on maintenance avelumab after gemcitabine/cisplatin and a man in his early 50s with a history of ulcerative colitis diagnosed with metastatic urothelial carcinoma, including brain involvement — Paul Markowski, MD and Gigi Chen, MD) (23:33) o Case: A woman in her early 80s with unresectable localized urothelial carcinoma; PD-L1 CPS 5, TMB low — Spencer H Bachow, MD (30:54) o Faculty presentation: Dr Rosenberg (36:21) • Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Siefker-Radtke o Case: A man in his mid 60s with metastatic bladder cancer and progressive disease on cisplatin/gemcitabine, now receiving sacituzumab govitecan — Priya Rudolph, MD, PhD (46:49) o Case: A man in his mid 60s with de novo metastatic urothelial bladder cancer now receiving pembrolizumab after gemcitabine/carboplatin (rapid progressive disease, FGFR3 mutation) — Yanjun Ma, MD (51:42) o Faculty presentation: Dr Siefker-Radtke (56:56) • Novel Investigational Agents and Strategies in the Treatment of mUBC — Dr Heath o Case: A man in his late 60s with metastatic urothelial carcinoma, PS 2 — Georges Azzi, MD (1:09:30) o Cases: A man in his mid 70s with metastatic mixed-histology (urothelial, small cell) bladder cancer who receives pembrolizumab and remains in remission 5 years later and a man in his early 50s with metastatic small cell carcinoma of the bladder who receives cisplatin, etoposide and durvalumab followed by maintenance durvalumab, now NED — Victoria Giffi, MD and Laurie Matt-Amaral, MD, MPH (1:13:48) o Faculty presentation: Dr Heath (1:19:43) CME information and select publications

Featuring perspectives from Dr Emmanuel Antonarakis, Prof Karim Fizazi, Dr Maha Hussain and Dr Matthew Smith, moderated by Dr Alan Bryce, including the following topics: • Management Approaches for Nonmetastatic Prostate Cancer — Dr Bryce o Introduction (00:00) o Case: A man in his early 70s with Gleason 8 prostate cancer after EBRT and leuprolide/enzalutamide, now receiving leuprolide/darolutamide with focal prostate uptake on PSMA PET — Priya Rudolph, MD, PhD (3:04) o Case: A man in his late 60s who underwent prostatectomy for Gleason 4 + 3 = 7 prostate cancer, now with increasing PSA levels — Nataliya Mar, MD (8:35) o Faculty presentation: Dr Bryce (15:12) • Optimizing the Care of Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Dr Hussain o Cases: A man in his early 70s with de novo mHSPC and a man in his mid 90s with de novo mHSPC — Georges Azzi, MD and Swati Vishwanathan, MD (23:29) o Case: A man in his early 70s with atrial fibrillation and rapid ventricular response who is diagnosed with de novo mHSPC (PSA 180,000 ng/mL) — Eric H Lee, MD, PhD (32:37) o Faculty presentation: Dr Hussain (37:34) • Current Therapeutic Options for Patients with Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Smith o Case: A man in his early 60s with de novo metastatic prostate cancer — Lai (Amber) Xu, MD, PhD (48:49) o Case: A man in his late 70s with mCRPC — Dr Rudolph (53:36) o Faculty presentation: Dr Smith (58:37) • Best Practice Management of mCRPC for Patients Harboring HRR Gene Alterations — Dr Antonarakis o Case: A man in his mid 70s with mCRPC with an ATM mutation who receives olaparib — Dr Vishwanathan (1:06:38) o Case: A man in his mid 70s with de novo mCRPC with a BRCA2 mutation who received multiple treatments and is now responding to olaparib but with transfusion-dependent neutropenia — Sunil Gandhi, MD (1:17:00) o Faculty presentation: Dr Antonarakis (1:21:30) • Current and Emerging Strategies for Patients with Recurrent mCRPC — Prof Fizazi o Case: A robust man in his mid 80s with mCRPC and rapid, symptomatic progressive disease through multiple treatments, now with extensive liver and bone metastases and small cell transformation — Vignesh Narayanan, MD (1:32:58) o Case: A man in his mid 70s with BRCA wild-type mHSPC who enrolls on a clinical trial of ADT/enzalutamide with or without a PD-1 inhibitor — David S Morris, MD (1:37:50) o Faculty presentation: Prof Fizazi (1:45:18) CME information and select publications

Featuring an interview with Drs Gottfried Konecny and Chirag Patel, including the following topics: • Tumor Treating Fields with Chirag B Patel, MD, PhD o Introduction (0:00) o Mechanism of action of tumor treating fields (5:53) o Tumor treating fields for glioblastoma multiforme (25:08) o Tumor treating fields for other tumor types (28:50) o Case presentations (34:10) • Updates on PARP Inhibitors in 2023 with Gottfried E Konecny, MD o PARP inhibitors as up-front maintenance therapy for ovarian cancer (37:15) o PARP inhibitors for recurrent ovarian cancer (44:34) CME information and select publications

Featuring perspectives from Dr Richard Finn, Dr Lipika Goyal and Prof Arndt Vogel, moderated by Dr Katie Kelley, including the following topics: • First-Line Treatment for Advanced Hepatocellular Carcinoma (HCC) — Dr Finn o Introduction (0:00) o Case: A man in his early 70s with newly diagnosed metastatic HCC receives atezolizumab/bevacizumab — Warren S Brenner, MD (2:27)) o Case: A woman in her late 50s with a history of hepatitis C and chronic kidney disease on dialysis with localized HCC after surgical resection; patient developed metastatic disease 10 months later — Liudmila N Schafer, MD (6:48) o Faculty presentation: Dr Finn (11:47) • Selection and Sequencing of Therapies for Relapsed/Refractory HCC — Dr Kelley o Case: A man in his mid 60s with metastatic HCC and a medical history of hepatitis C develops interstitial lung disease on atezolizumab/bevacizumab — Priya Rudolph, MD (21:48) o Cases: A man in his late 60s with post-transplant recurrence develops metastatic HCC and receives lenvatinib followed by cabozantinib followed by regorafenib and a man in his late 70s with metastatic HCC after treatment with atezolizumab/bevacizumab, lenvatinib and currently cabozantinib — Lionel A Kankeu Fonkoua, MD and Susmitha Apuri, MD (26:58) o Faculty presentation: Dr Kelley (35:56) • Current and Future Role of Immunotherapy in the Treatment of Advanced Biliary Tract Cancers (BTCs) — Prof Vogel o Case: A woman in her mid 70s with metastatic cholangiocarcinoma who received first-line gemcitabine/cisplatin with durvalumab — Dr Brenner (45:40) o Case: A man in his early 70s with localized cholangiocarcinoma deemed potentially resectable with tumor response — Jeremy Lorber, MD (50:23) o Faculty presentation: Dr Vogel (55:10) • Integration of Targeted Therapy into the Management of Advanced BTCs — Dr Goyal o Cases: A woman in her late 70s with intrahepatic cholangiocarcinoma considered unresectable — an FGFR2-KIAA1598 fusion was detected on NGS and a man in his early 60s with metastatic cholangiocarcinoma with severe muscle pain on pemigatinib — Dr Fonkoua and Joseph Martins, MD (1:06:18) o Cases: A man in his early 50s with recurrent metastatic cholangiocarcinoma with a BRAF V600E mutation treated with dabrafenib/trametinib and a woman in her mid 60s with cholangiocarcinoma with an IDH1 mutation receives ivosidenib — Farshid Dayyani, MD, PhD and Niyati A Nathwani, MD (1:12:26) o Faculty presentation: Dr Goyal (1:19:08) CME information and select publications

Proceedings from a symposium in partnership with NCOA and SCOS, featuring perspectives from Drs Ibiayi Dagogo-Jack and Stephen V Liu on recent advances and real-world implications in lung cancer. CME information and select publications

Proceedings from a symposium in partnership with NCOA and SCOS, featuring perspectives from Drs Michael Birrer and Ursula Matulonis on recent advances and real-world implications in gynecologic cancers. CME information and select publications

Proceedings from a symposium in partnership with NCOA and SCOS, featuring perspectives from Drs Danielle Brander and Craig Moskowitz on recent advances and real-world implications in chronic lymphocytic leukemia and lymphomas. CME information and select publications

Proceedings from a symposium in partnership with NCOA and SCOS, featuring perspectives from Drs Daniel Petrylak and Sandy Srinivas on recent advances and real-world implications in genitourinary cancers. CME information and select publications

Proceedings from a symposium in partnership with NCOA and SCOS, featuring perspectives from Drs Tanios Bekaii-Saab and Rutika Mehta on recent advances and real-world implications in gastrointestinal cancers. CME information and select publications

Proceedings from a symposium in partnership with NCOA and SCOS, featuring perspectives from Drs Harold Burstein and Virginia Kaklamani on recent advances and real-world implications in breast cancer. CME information and select publications

Featuring perspectives from Prof Laurence Albiges, Dr Toni Choueiri and Prof Thomas Powles, moderated by Dr Brian Rini, including the following topics: • Available Data with and Ongoing Investigation of Immune Checkpoint Inhibitors for Nonmetastatic Renal Cell Carcinoma (RCC) — Prof Powles o Introduction (0:00) o Case: A woman in her early 60s after left nephrectomy (T3aN0M0 clear cell carcinoma) — Swati Vishwanathan, MD (1:39) o Cases: A man in his early 50s develops renal dysfunction after 2 cycles of adjuvant pembrolizumab for RCC and a man in his late 60s with Stage III clear cell RCC (ccRCC) discontinues adjuvant pembrolizumab due to severe musculoskeletal pain and joint swelling — Justin Peter Favaro, MD, PhD and Priya Rudolph, MD, PhD (6:05) o Faculty presentation: Prof Powles (11:03) • Evidence-Based Selection of First-Line Therapy for Metastatic RCC — Dr Choueiri o Case: A man in his early 70s with metastatic RCC enrolls on the PDIGREE trial and receives nivolumab/ipilimumab without response followed by cabozantinib — Helen H Moon, MD (21:32) o Cases: A man in his early 70s receives ipilimumab/nivolumab for widely metastatic RCC and develops autoimmune hepatitis and a man in his early 60s with metastatic ccRCC receives ipilimumab/nivolumab followed by nivolumab with response but develops hypothyroidism and hypoadrenalism — Victoria Giffi, MD and Philip L Brooks, MD (25:33) o Faculty presentation: Dr Choueiri (36:38) • Treatment Options for Relapsed/Refractory RCC — Dr Rini o Case: A woman in her early 60s with metastatic ccRCC receives lenvatinib/pembrolizumab but develops difficult-to-manage hypertension — Eric H Lee, MD, PhD (46:04) o Case: A woman in her mid 60s with metastatic ccRCC and somatic VHL gene mutation receives ipilimumab/nivolumab and develops a solitary brain metastasis — Sunil Gandhi, MD (52:36) o Faculty presentation: Dr Rini (57:54) • Management of RCC Among Special Patient Populations — Prof Albiges o Case: A man in his late 60s with Waldenström macroglobulinemia and metastatic papillary RCC receives first-line ipilimumab/nivolumab followed by nivolumab but develops disease progression, including brain metastases — Nikesh Jasani, MD (1:07:58) o Case: A woman in her early 70s with a history of psoriatic arthritis develops metastatic ccRCC, receives pembrolizumab/axitinib and develops elevated liver function tests — Georges Azzi, MD (1:12:38) o Faculty presentation: Prof Albiges (1:18:45) CME information and select publications

Featuring perspectives from Dr Christopher Lieu, including the following topics: • Early-Onset Colorectal Cancer o Introduction (00:00) • Localized Disease o Case: A woman in her mid 30s with left-sided T3N0 Grade II obstructing adenocarcinoma of the colon — William R Mitchell, MD (16:31) o Case: A woman in her early 50s with Stage II mismatch repair-proficient sigmoid colon cancer with focal intramural lymphovascular invasion after 6 cycles of adjuvant capecitabine — Priya Rudolph, MD, PhD (19:51) • Metastatic Disease o Case: A woman in her mid 80s with pan-RAS wild-type (WT) metastatic rectal cancer with poor tolerance to chemotherapy, now receiving regorafenib with slowly progressive disease — Eric H Lee, MD, PhD (32:09) o Case: A man in his early 60s with recurrent, microsatellite stable, HER2-negative, RAS WT rectal cancer, currently receiving TAS-102/bevacizumab — Swati Vishwanathan, MD (35:16) • HER2-Positive Disease o Case: A woman in her mid 50s with RAS WT, HER2-amplified metastatic colon adenocarcinoma — Gigi Chen, MD (44:38) o Case: A woman in her mid 60s with multiregimen-relapsed RAS WT, HER2-positive metastatic rectal cancer, now receiving trastuzumab/tucatinib — Sunil Gandhi, MD (50:47) • Microsatellite Instability-High Disease; BRAF-Mutant Disease o Case: A woman in her late 70s with HER2-negative, BRAF V600E-mutant, microsatellite stable metastatic colon cancer after mFOLFOX/bevacizumab followed by maintenance 5-FU/bevacizumab — Victoria Giffi, MD (58:14) CME information and select publications

Inside the Issue — Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer | Faculty Presentation 2: Tolerability and Other Practical Issues with OFS, Including Its Potential Utility in Preserving Fertility — Dr Ann Patridge CME information and select publications

Inside the Issue — Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer | Faculty Presentation 1: Optimizing the Use of Ovarian Function Suppression (OFS)/Ablation in the Care of Patients with Breast Cancer — Dr Kathy Miller CME information and select publications

Featuring perspectives from Dr Matthew Lunning, including the following topics: · Introduction (00:00) · Case: A woman in her mid 20s with T1cN0M0, ER/PR-positive, HER2-negative breast cancer, Recurrence Score® (RS) of 26 — Dr Partridge (10:03) · Case: A woman in her late 20s with a 2.8-cm ER/PR-positive, HER2-positive Grade III intraductal carcinoma — Dr Miller (26:42) · Case: A woman in her mid 30s with a 3.5-cm ER/PR-negative, HER2-negative breast cancer with a BRCA2 mutation — Dr Partridge (41:01) · Case: A woman in her early 30s with ER/PR-positive, HER2-negative inflammatory breast cancer — Dr Miller (52:28) CME information and select publications

Featuring perspectives from Dr Yelena Janjigian, Prof Florian Lordick and Dr Zev Wainberg, moderated by Dr Samuel Klempner, including the following topics: • Optimizing the Selection of Therapy for Newly Diagnosed Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer — Dr Klempner o Introduction (0:00) o Case: A man in his mid 50s with HER2-negative gastroesophageal adenocarcinoma (PD-L1 100%) — Victoria Giffi, MD (1:15) o Cases: A woman in her early 80s with a history of Stage 0 chronic lymphocytic leukemia, now with unresectable gastric adenocarcinoma, develops Coombs-positive hemolytic anemia after 2 cycles of FOLFOX and nivolumab and a man in his early 60s with localized adenocarcinoma of the GEJ receives the CROSS regimen but is found at surgery to have metastatic disease and tumor NGS demonstrates an ARID1A mutation — Matthew R Strickland, MD and Priya Rudolph, MD, PhD (8:05) o Faculty presentation: Dr Klempner (14:05) • Current Considerations in the Treatment of HER2-Positive Advanced Gastric/GEJ Adenocarcinoma — Dr Janjigian o Case: A woman in her early 30s with newly diagnosed metastatic HER2-amplified signet cell gastric adenocarcinoma — Farshid Dayyani, MD, PhD (22:36) o Cases: A man in his mid 80s with newly diagnosed HER2-positive gastroesophageal cancer metastatic to the liver and lung, tumor 3+ by IHC for HER2 with a PD-L1 of 10 and a woman in her mid 70s with HER2-positive esophageal adenocarcinoma and brain metastases after stereotactic radiosurgery — Warren S Brenner, MD and Dr Strickland (31:43) o Faculty presentation: Dr Janjigian • Selection and Sequencing of Therapy for Relapsed/Refractory Gastric/GEJ Cancer; Novel Investigational Approaches — Prof Lordick o Cases: A woman in her mid 70s with Lynch syndrome and a history of Stage III colon cancer presents with poorly differentiated GEJ carcinoma with liver and lung metastases and a man in his early 60s presents with a 70-lb weight loss and locally advanced high-grade neuroendocrine carcinoma of the distal esophagus — Namrata I Peswani, MD and Ranju Gupta, MD (46:19) o Case: A man in his early 60s with metastatic gastric adenocarcinoma (PD-L1 CPS 0) with clinical and radiographic progression of disease after 4 cycles of FOLFOX — Dr Strickland (52:31) o Faculty presentation: Prof Lordick (55:26) • Current Approaches to the Management of Esophageal Cancer — Dr Wainberg o Cases: A man in his late 50s with dysphagia, weight loss and a lower esophageal adenocarcinoma (T3N3) and a man in his mid 70s with dysphagia is found to have a lower esophageal adenocarcinoma with regional adenopathy and pulmonary nodules (CPS 40 by SP263) — Gurveen Kaur, MD and Liudmila N Schafer, MD (1:03:56) o Case: A woman in her early 60s with a known germline BRCA2 mutation and a history of Hodgkin lymphoma, breast and anaplastic thyroid cancers now has localized squamous cell esophageal cancer — Dr Brenner (1:11:56) o Faculty presentation: Dr Wainberg (1:17:49) CME information and select publications

Featuring perspectives from Dr D Ross Camidge, Dr Justin Gainor, Prof Benjamin Solomon and Prof Solange Peters, including the following topics: • Evolving Understanding and Management of Non-Small Cell Lung Cancer (NSCLC) with Targeted Mutations (0:00) • Adjuvant Therapy for Patients with NSCLC with Targetable Mutations (11:17) • Family Planning for Patients with Cancer (23:50) • Optimal Identification of ALK-Positive Metastatic NSCLC — Dr Camidge (30:33) • Selection of First-Line Treatment for ALK-Positive NSCLC — Dr Gainor (49:22) • Sequencing and Selection of Therapy for Relapsed/Refractory ALK-Positive NSCLC — Prof Peters (1:23:33) • Managing Side Effects of ALK Tyrosine Kinase Inhibitors (TKIs) — Prof Solomon (1:39:14) • Case: A woman in her early 40s with Stage IIIB ALK-positive NSCLC who received alectinib for more than 4 years — Dr Gainor (1:59:37) • Case: A woman in her mid 50s who remains in complete response with lorlatinib after 4 years — Prof Solomon (2:03:52) • Case: A woman in her early 60s with Stage IV NSCLC with ALK translocation who received lorlatinib followed by alectinib — Prof Peters (2:10:18) • Case: A woman in her late 60s with ALK-positive NSCLC who continues to receive brigatinib after discontinuation of alectinib due to concerns of drug-induced pneumonitis — Dr Camidge (2:15:44) • Case: A woman in her late 40s with NSCLC with an ALK fusion who received multiple ALK TKIs — Dr Gainor (2:21:11) • Case: A man in his early 30s with ALK-positive NSCLC and brain metastases who continues to receive lorlatinib after 6 years — Prof Solomon (2:26:33) CME information and select publications

Featuring perspectives from Dr Matthew Lunning, including the following topics: • Potential role of polatuzumab vedotin/R-CHP in therapy for previously untreated diffuse large B-cell lymphoma (DLBCL) (00:00) • Association between metabolic tumor volume and clinical outcomes with loncastuximab tesirine in the LOTIS-2 trial and axicabtagene ciloleucel in the ZUMA-7 trial (10:54) • Chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphomas: Activity, tolerability and patient selection (22:16) • Efficacy of and durable complete responses with bispecific antibodies in patients with DLBCL (36:48) • Five-year results and overall survival update from the Phase III AUGMENT study evaluating rituximab and lenalidomide (R2) versus rituximab and placebo for relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (42:44) • Activity and safety of tazemetostat in combination with (R2) in patients with R/R follicular lymphoma (FL) (44:52) • Long-term clinical outcomes with CAR T-cell therapies for patients with R/R FL (46:50) • Available data with and ongoing studies of bispecific antibodies for R/R FL (50:23) • Design and outcomes of the SHINE and TRIANGLE studies in mantle cell lymphoma (MCL); evolving role of transplantation for MCL (1:00:38) • Real-time monitoring of minimal residual disease in patients receiving acalabrutinib with (R2) for treatment-naïve MCL (1:13:29) • Assessment of durable responses after brexucabtagene autoleucel for R/R MCL in the ZUMA-2 trial (1:15:29) • High complete response rates with glofitamab for patients with heavily pretreated MCL (1:19:00) • Nivolumab with ICE (ifosfamide/carboplatin/etoposide) as first salvage therapy for patients with high-risk R/R Hodgkin lymphoma (1:21:04) • Efficacy and safety of camidanlumab tesirine in patients with R/R classical Hodgkin lymphoma (1:23:07) • Importance of brain-to-vein time in patients receiving CAR T-cell therapy (1:25:37) CME information and select publications

Featuring a slide presentation and related discussion from Dr Mrinal Gounder, including the following topics: • Efficacy and tolerability of sorafenib in patients with advanced and refractory desmoid tumors (00:00) • DESMOPAZ: Results of a Phase II trial of pazopanib versus IV methotrexate/vinblastine for progressive desmoid tumors (1:59) • Results of the pivotal Phase III DeFi trial evaluating the gamma secretase inhibitor (GSI) nirogacestat for progressing desmoid tumors (3:40) • Initial results of the Phase II/III RINGSIDE study of the GSI AL102 for the treatment of desmoid tumors (19:47) CME information and select publications

Featuring perspectives from Dr Mrinal Gounder, including the following topics: • Incidence and prevalence of desmoid tumors (00:00) • Outcomes associated with historical management paradigms for desmoid tumors (17:15) • Rationale for targeting the gamma secretase complex and Notch pathway as a therapeutic approach for desmoid tumors; mechanism of action of nirogacestat (20:56) • Key efficacy outcomes from the Phase III DeFi trial evaluating the gamma secretase inhibitor nirogacestat versus placebo for progressing desmoid tumors (30:14) • Spectrum and frequency of adverse events, including ovarian dysfunction, with nirogacestat (36:06) CME information and select publications

Featuring perspectives from Dr Komal Jhaveri, including the following topics: • Case: A premenopausal woman in her early 40s with a 5.8-cm, ER/PR-positive, HER2-negative infiltrating lobular carcinoma and microscopic sentinel node involvement — Arielle Heeke, MD (11:58) • Case: A premenopausal woman in her early 40s with a 3.1-cm ER/PR-positive, HER2-negative localized invasive ductal carcinoma (IDC) and a Recurrence Score® of 18 — Alan B Astrow, MD (14:51) • Case: A woman in her late 50s with ER/PR-positive, HER2-negative, microsatellite stable, BRCA1/2 wild-type, metastatic IDC with PALB2 mutation who receives palbociclib/letrozole and zoledronic acid — Shaachi Gupta, MD, MPH (19:37) • Case: A postmenopausal woman in her early 60s with de novo ER/PR-positive, HER2-low (IHC 1+) metastatic IDC after disease progression on abemaciclib/letrozole and alpelisib/fulvestrant — Zanetta S Lamar, MD (29:32) • Case: A premenopausal woman in her mid 30s with ER/PR-positive, HER2-negative IDC receiving neoadjuvant chemotherapy and goserelin, now with sexual dysfunction — Laila Agrawal, MD (34:48) • Case: A woman in her mid 60s with ER/PR-positive, HER2-low bone-only metastatic IDC on endocrine therapy alone since 2001, now experiencing asymptomatic disease progression (ESR1 variant, AKT1 mutation on liquid biopsy) — Philip L Brooks, MD (45:55) CME information and select publications

Featuring perspectives from Drs Farrukh Awan and Kelly Rogers, including the following topics: • Case: A woman in her early 90s with underlying chronic obstructive pulmonary disease was observed for 20 years for chronic lymphocytic leukemia (CLL) before initiating treatment with acalabrutinib and quickly develops fatigue, headache and diarrhea — Erik Rupard, MD (16:56) • Case: A frail man in his late 80s with CLL requiring treatment develops nonspecific side effects with acalabrutinib — Neil Morganstein, MD (29:44) • Case: A man in his late 80s with CLL was observed for 28 years before starting ibrutinib and then develops atrial fibrillation — Laurie Matt-Amaral, MD, MPH (35:05) • Case: A man in his mid 80s with CLL develops atrial fibrillation on ibrutinib while traveling overseas — Eric H Lee, MD, PhD (39:17) • Case: A man in his mid 60s with relapsed CLL treated with ibrutinib develops significant epistaxis and ecchymoses — Yanjun Ma, MD (49:01) • Case: A man in his early 60s with Waldenström macroglobulinemia receives ibrutinib/rituximab and develops elevated liver enzymes — Gigi Chen, MD (51:20) • Case: A woman in her late 60s with CLL experiences acalabrutinib-associated headaches — Rohit Gosain, MD (54:10) • Case: A man in his early 70s presents with relapsed mantle cell lymphoma after receiving bendamustine/rituximab on a clinical trial followed by acalabrutinib on progression — Zanetta S Lamar, MD (57:21) CME information and select publications

Featuring perspectives from Drs Tanios Bekaii-Saab, Scott Kopetz, and John Strickler and Prof Eric Van Cutsem, moderated by Dr Kristen Ciombor, including the following topics: • Integration of Therapies Targeting BRAF and HER2 in Metastatic Colorectal Cancer (mCRC) — Dr Strickler o Introduction (0:00) o Case: A man in his early 40s presenting with microsatellite-stable (MSS) rectal cancer and liver metastases — Victoria Giffi, MD (2:04) o Cases: A man in his late 70s with HER2-amplified colon cancer and extensive liver metastases and a man in his late 50s with KRAS G12S-mutant HER2-amplified colon cancer and lung metastases — Ranju Gupta, MD and Shaachi Gupta, MD, MPH (9:12) o Faculty presentation (16:39) • Optimizing the Use of Immune Checkpoint Inhibitors in the Management of mCRC — Dr Ciombor o Case: A man in his mid 50s with BRAF V600E-mutant, KRAS/NRAS wild-type metastatic colon cancer with disease progression on FOLFOXIRI/bevacizumab — Lai (Amber) Xu, MD, PhD (26:13) o Case: A man in his late 60s with localized unresectable microsatellite instability-high carcinoma of the cecum — Farshid Dayyani, MD, PhD (32:02) o Faculty presentation (41:11) • Evidence-Based Selection and Sequencing of Therapy for Patients with mCRC — Prof Van Cutsem o Case: A man in his late 70s with metastatic rectal cancer and newly diagnosed PMS2-positive Lynch syndrome — Liudmila N Schafer, MD (51:39) o Case: A man in his mid 50s with pan-RAS wild-type metastatic rectal cancer treated with FOLFOX/cetuximab — Warren S Brenner, MD (56:55) o Faculty presentation (1:03:36) • Promising Agents and Strategies for Patients with mCRC — Dr Bekaii-Saab o Case: A woman in her early 50s with KRAS and BRAF wild-type, HER2-negative T3N1 rectal cancer with liver and lung oligometastases who underwent multiple ablations and stereotactic body radiation therapy and is currently receiving FOLFIRI/panitumumab – MSS, mismatch repair-proficient, PD-L1 0% — Jennifer L Dallas, MD (1:13:13) o Case: A woman in her early 60s with metastatic KRAS G12C-mutant cancer of the sigmoid colon — Philip L Brooks, MD (1:18:43) o Faculty presentation (1:22:32) • The Changing Management Paradigm for Localized CRC — Dr Kopetz o Case: A man in his early 70s with 2 synchronous T3N0 cancers of the splenic flexure and cecum who is found to have circulating tumor DNA after resection — Dr Brenner (1:35:56) o Case: A man in his early 80s with a Stage II obstructing cancer of the right colon — Namrata I Peswani, MD (1:46:12) o Faculty presentation (1:47:58) CME information and select publications

Featuring perspectives from Dr Bob Li, including the following topics: • Evolution of targeted therapy for HER2-altered non-small cell lung cancer (NSCLC) (0:00) • Incidence and management of HER2 amplifications and mutations in NSCLC (10:45) • Role of ErbB/HER protein family biology in lung cancer (19:03) • Current and emerging roles of antibody-drug conjugates in lung cancer (33:43) • Considerations for clinical trial participation and improving access to care for patients with cancer (55:08) • Management of trastuzumab deruxtecan-associated interstitial lung disease (1:03:18) • Future of HER2-targeted therapy in lung cancer and beyond (1:14:39) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hodgkin and Non-Hodgkin Lymphomas — Faculty Presentation 2: Follicular Lymphoma and Mantle Cell Lymphoma — Dr Laurie Sehn CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hodgkin and Non-Hodgkin Lymphomas — Faculty Presentation 1: Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma — Dr Christopher Flowers CME information and select publications

Featuring perspectives from Drs Christopher Flowers and Laurie Sehn, including the following topics: • Introduction (0:00) • Treatment for Diffuse Large B-Cell Lymphoma (7:45) • Management of Hodgkin Lymphoma (35:33) • Follicular Lymphoma (41:57) • Caring for Patients with Mantle Cell Lymphoma (51:38) CME information and select publications

Featuring perspectives from Drs Jonathan Strosberg and Lori Wirth, including the following topics: Nontargeted Treatment for Thyroid Cancer Introduction (0:00) Case: A woman in her late 60s with poorly differentiated thyroid cancer initially treated with lenvatinib – Dr Wirth (6:05) NTRK Fusions in Thyroid Cancer Case: A woman in her early 60s with metastatic papillary thyroid cancer with an NTRK fusion who received repotrectinib – Eric Sherman, MD (13:27) Case: A man in his early 60s with metastatic papillary thyroid cancer with NTRK fusion who received larotrectinib – Dr Wirth (18:37) RET Mutations/Fusions in Thyroid Cancer Case: A man in his early 40s who presents with metastatic medullary thyroid cancer with a RET mutation – Dr Sherman (21:43) Case: A man in his early 40s with metastatic medullary thyroid cancer with a RET mutation who received selpercatnib – Dr Wirth (27:49) Somatostatin Analogs for Neuroendocrine Tumors (NETs) Case: A woman in her early 50s with a newly well-differentiated small-bowel NET and low-volume liver metastases – Pamela Kunz, MD (33:41) Management of Carcinoid Syndrome with NETs Cases: A man in his early 60s with a well-differentiated small-bowel NET with stable disease on octreotide who is now experiencing increasing diarrhea and a man in his early 60s who received telotristat ethyl for carcinoid syndrome diarrhea – Dr Kunz and Dr Strosberg (41:25) Von Hippel-Lindau-Associated Pancreatic NETs Case: A woman in her late 40s with von Hippel-Lindau syndrome and a pancreatic NET who received belzutifan – Dr Strosberg (49:42) Case: A man in his early 60s with a symptomatic, well-differentiated hypervascular pancreatic NET with bulky liver metastases – Dr Kunz (55:38) CME information and select publications

Featuring perspectives from Dr Noopur Raje, including the following topics: • Introduction (0:00) • Case: A man in his early 80s who presents with renal failure (creatine = 7) and standard-risk multiple myeloma (MM) — Swati Vishwanathan, MD (14:22) • Case: A man in his late 60s with a large sternal plasmacytoma — Warren S Brenner, MD (20:35) • Case: A man in his early 60s who presents with multiple bone lesions and t(4;14), (1q21+) MM — Hans Lee, MD (23:21) • Case: A man in his late 30s with standard-risk MM who receives RVd followed by autologous stem cell transplant and has been on maintenance lenalidomide for 3.5 years — Yanjun Ma, MD (32:32) • Case: An asymptomatic woman in her mid 60s with quadruple-refractory MM with multiple prior serious infections — Neil Morganstein, MD (40:38) • Faculty Survey (53:19) • Case: A woman in her mid 70s with MM who developed severe peripheral neuropathy from induction RVd — Ranju Gupta, MD (57:45) CME information and select publications

Featuring a slide presentation and related discussion from Dr Edward Garon, including the following topics: • Immune checkpoint inhibitor therapy for treatment-naïve advanced non-small cell lung cancer (NSCLC) without an actionable mutation (0:00) • Duration of immunotherapy in the frontline setting for NSCLC with no targetable mutation (13:43) • New treatment strategies for relapsed or refractory NSCLC with no targetable mutation (16:25) • Management of antibody-drug conjugate-associated toxicity (19:08) • Activity of antibody-drug conjugates alone or in combination with anti-PD-1 antibodies (26:18) CME information and select publications

Featuring an interview with Dr Edward Garon, including the following topics: Treatment of non-small cell lung cancer (NSCLC) today versus prior to the availability of immune checkpoint inhibitors (0:00) Current and emerging roles of antibody-drug conjugates in NSCLC (3:30) Optimal workup for patients presenting with metastatic NSCLC; role of biomarker assessment (5:02) Considerations for the addition of an anti-CTLA-4 antibody to the treatment regimen for NSCLC (17:30) Correlation between immune-related toxicity and the efficacy of immune checkpoint inhibitors (21:47) Case: A woman in her mid 60s with multiple comorbidities presenting with NSCLC with a KRAS G12A mutation, pleural effusion and extensive bone metastases (24:35) Case: A man in his mid 50s with a long smoking history presenting with squamous cell carcinoma of the lung (31:07) Case: A woman in her early 60s with NSCLC with an EGFR L858R mutation who is relapsing after treatment with multiple therapies (37:22) Language barriers leading to disparities in clinical trial enrollment (44:38) CME information and select publications

Featuring perspectives from Dr Srdan Verstovsek, including the following topics: Overview of current issues in the management of myeloproliferative neoplasms (MPN) (0:00) Treatment strategies for patients with myelofibrosis (MF) progressing after ruxolitinib (14:46) Correlation of molecular characterization and response to ruxolitinib in patients with MF (23:57) Rationale for and efficacy with combined inhibition of Bcl-2 and Bcl-xL for MPN (44:38) Targeting calreticulin mutations for MPN (52:02) Advances in the management of polycythemia vera (57:54) Developments in the care of patients with essential thrombocythemia (1:04:43) Future directions in the clinical care of patients with MPN (1:12:46) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gynecologic Oncology — Faculty Presentation 2: Endometrial and Cervical Cancer — Dr Krishnansu Tewari CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gynecologic Oncology — Faculty Presentation 1: Ovarian Cancer — Dr Kathleen Moore CME information and select publications

Featuring perspectives from Drs Michael Birrer and Kathleen Moore, including the following topics: Gynecologic Oncology Introduction (0:00) Ovarian Cancer PARP inhibitors as primary maintenance (8:11) PARP inhibitors for recurrent and metastatic disease (19:04) Antibody-drug conjugates: Mirvetuximab soravtansine; upifitamab rilsodotin (31:39) Endometrial Cancer Immunotherapy for metastatic disease (43:49) Selinexor as maintenance therapy (51:33) Other novel agents (56:52) Cervical Cancer Immunotherapy for metastatic disease and the antibody-drug conjugate tisotumab vedotin (1:01:00) CME information and select publications

Featuring a slide presentation and related discussion from Dr Gilles Salles, including the following topics: Recent data with polatuzumab vedotin/bendamustine/rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) (0:00) Available data from trials evaluating tafasitamab/lenalidomide, loncastuximab tesirine and selinexor for DLBCL (12:57) Current and future roles of chimeric antigen receptor (CAR) T-cell therapy, bispecific antibodies and combination therapies for DLBCL (21:43) CME information and select publications

Featuring an interview with Dr Gilles Salles, including the following topics: Biology underlying B-cell lymphomas, role of Bruton tyrosine kinase (BTK) inhibitors in lymphomas and reason for cure in diffuse large B-cell lymphoma (DLBCL) versus indolent lymphomas (0:00) Efficacy, tolerability and optimal sequencing of selinexor, polatuzumab vedotin/bendamustine/rituximab, tafasitamab/lenalidomide and loncastuximab tesirine for DLBCL (6:32) Ongoing trials evaluating selinexor, tafasitamab/lenalidomide and loncastuximab tesirine for DLBCL (14:24) Managing cytokine release syndrome associated with bispecific antibodies; eligibility considerations with bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy (18:02) Case: A man in his late 60s diagnosed with DLBCL who has a history of ulcerative colitis and mitral valve repair (28:17) Case: A woman in her early 80s with transformed DLBCL (35:14) Case: A woman in her early 40s with DLBCL unresponsive to CAR T-cell therapy (38:05) CME information and select publications

Featuring perspectives from Dr Richard Stone, including the following topics: Current and future trends in the care of patients with acute myeloid leukemia (AML) (0:00) Management of AML with IDH1/2 and FLT3 mutations (17:28) Advances in the treatment of high-risk AML (29:42) Emerging data with novel therapies for AML with targetable mutations (36:53) Hematopoietic stem cell transplantation as a treatment option for patients with relapsed or refractory AML (51:15) Advances in the care of patients with myelodysplastic syndromes (56:19) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma — Faculty Presentation 2: Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Other Novel Approaches for MM — Dr Ajay Nooka CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma — Faculty Presentation 1: Optimizing the Current Management of Multiple Myeloma (MM) — Dr Joseph Mikhael CME information and select publications

Featuring perspectives from Drs Joseph Mikhael and Ajay Nooka, including the following topics: Introduction (0:00) Front-Line Treatment; Autologous Stem Cell Transplant (11:36) Use of Anti-CD38 Antibodies (29:36) CAR T-Cell Therapy (38:16) Treatment with Bispecific Antibodies (48:59) Other Treatments for Relapsed/Refractory Disease (56:07) CME information and select publications

Featuring perspectives from Drs Erica Mayer and Ruth O'Regan, including the following topics: Pregnancy during adjuvant endocrine therapy; fertility issues (0:00) Genomic biomarkers in the adjuvant setting (16:28) CDK4/6 inhibitors in metastatic disease (31:58) Adjuvant use of CDK4/6 inhibitors (47:42) Novel agents in metastatic disease (1:14:26) CME information and select publications

Featuring a slide presentation and related discussion from Professor Giuseppe Curigliano, including the following topics: Recent data with targeted therapies for patients with HER2-positive metastatic breast cancer (0:00) Case: A woman in her early 40s with a new right breast tumor 10 years after adjuvant radiation and endocrine therapy (17:17) Case: A woman in her mid 20s with a family history of breast cancer presenting with a lump in her left breast (26:34) CME information and select publications

Featuring an interview with Professor Giuseppe Curigliano, including the following topics: Vision for treating and curing HER2-positive metastatic breast cancer (mBC) in the future (0:00) Optimal treatment of HER2-positive mBC with brain metastases (7:42) Screening for and management of T-DXd-related interstitial lung disease (17:32) Gastric toxicities associated with the tucatinib/trastuzumab/capecitabine regimen and with T-DXd; differences in the toxicity profiles of these therapies between patients with HER2-positive and HER2-low breast cancer (23:50) Approach to endocrine therapy for triple-positive disease; emerging data with the AKT inhibitor capivasertib (28:43) Case: A woman in her mid 40s with a family history of breast cancer and upper limb soft tissue sarcoma who presents with a right breast lump and axillary adenopathy on self-examination (35:44) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer — Faculty Presentation 2: Therapeutic Approaches for Patients with Other Actionable Genomic Alterations — Dr Gregory Riely CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer — Faculty Presentation 1: Management of Non-Small Cell Lung Cancer with an EGFR, ALK or ROS1 Abnormality — Dr Zofia Piotrowska CME information and select publications

Featuring perspectives from Drs Zofia Piotrowska and Gregory Riely, including the following topics: Introduction: What Is Targeted Therapy? (0:00) EGFR-Activating Mutations (12:23) EGFR Exon 20 Insertion Mutations (27:54) ALK and ROS1 Rearrangements (31:31) HER2 Mutations (36:17) NRG1 Fusions (45:39) RET Fusions (49:07) MET Exon 14 Mutations (53:10) KRAS G12C Mutations (56:01) CME information and select publications